| Literature DB >> 29505559 |
Osman N Yogurtcu1, Margaret E Johnson1.
Abstract
Cell division, endocytosis, and viral budding would not function without the localization and assembly of protein complexes on membranes. What is poorly appreciated, however, is that by localizing to membranes, proteins search in a reduced space that effectively drives up concentration. Here we derive an accurate and practical analytical theory to quantify the significance of this dimensionality reduction in regulating protein assembly on membranes. We define a simple metric, an effective equilibrium constant, that allows for quantitative comparison of protein-protein interactions with and without membrane present. To test the importance of membrane localization for driving protein assembly, we collected the protein-protein and protein-lipid affinities, protein and lipid concentrations, and volume-to-surface-area ratios for 46 interactions between 37 membrane-targeting proteins in human and yeast cells. We find that many of the protein-protein interactions between pairs of proteins involved in clathrin-mediated endocytosis in human and yeast cells can experience enormous increases in effective protein-protein affinity (10-1000 fold) due to membrane localization. Localization of binding partners thus triggers robust protein complexation, suggesting that it can play an important role in controlling the timing of endocytic protein coat formation. Our analysis shows that several other proteins involved in membrane remodeling at various organelles have similar potential to exploit localization. The theory highlights the master role of phosphoinositide lipid concentration, the volume-to-surface-area ratio, and the ratio of 3D to 2D equilibrium constants in triggering (or preventing) constitutive assembly on membranes. Our simple model provides a novel quantitative framework for interpreting or designing in vitro experiments of protein complexation influenced by membrane binding.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29505559 PMCID: PMC5854442 DOI: 10.1371/journal.pcbi.1006031
Source DB: PubMed Journal: PLoS Comput Biol ISSN: 1553-734X Impact factor: 4.475
Fig 1Quantifying how protein binding partners in solution can increase complex formation by binding to lipids on membrane surfaces.
This model contains two types of proteins (P1 and P2) and one type of lipid (M). We show all ten possible binding interactions that can occur between this pair of proteins that bind each other (P1+P2⇌P1P2) and also bind specific lipids (M), producing a system of nine total distinct species: P1, P2, M, P1P2, MP1, P2M, MP1P2, P1P2M, and MP1P2M. a) Solution (3D) binding. b) Interactions in solution (3D) that pull proteins to the membrane surface through protein or lipid binding. In (c-e) the binding interactions are in 2D (species concentration in Area-1) and can exploit the lower search space. Conversion from 3D to 2D equilibrium constant is defined by the variable σ, where only σ = σPP appears in Eq 3. To solve for all species in consistent units (i.e. Volume-1), Ka2D values must be multiplied by V/A. The size of solution volume V vs. membrane surface area A is thus a critical parameter controlling binding enhancement. The membrane surface can be the plasma membrane, for example, but also liposomes suspended in solution. d,e) Proteins localized at the surface will also bind lipids in a 2D search. There are over 100 functionally diverse peripheral membrane proteins in yeast alone [14] whose binding interactions with one another could strengthen substantially via binding to membranes. We simulated this model for a comprehensive range of conditions using mainly systems of ordinary differential equations (ODE), but also single-particle reaction-diffusion (RD) simulations [19, 20] (Methods).
Proteins studied, copy numbers, protein-lipid interactions (PLI) and affinities (KdPM).
| Protein | Species | Copy | KdPM | Literature Refs | |
|---|---|---|---|---|---|
| 1 | OSH2 | Yeast | 850 | 1–1.5 | PLI: PMID:11238399. Affinity, measured: same ref. |
| 2 | SWH1 | Yeast | 505 | 3.5–6.2 | PLI: PMID:21119626. Affinity, measured: same ref. |
| 3 | KES1 | Yeast | 21166 | 0.055–2.2 | PLI: PMID:22162133,11916983. Affinity, measured: same. |
| 4 | VPS17 | Yeast | 1077 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 5 | SNX4 | Yeast | 1483 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 6 | SNX41 | Yeast | 367 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 7 | VPS5 | Yeast | 1326 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 8 | ATG20 | Yeast | 519 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 9 | BOI2 | Yeast | 567 | 6.6–19.5 | PLI: PMID:15023338. Affinity, measured: same ref. |
| 10 | CLA4 | Yeast | 397 | 20.2–100 | PLI: PMID:15023338. Affinity, measured: same ref. |
| 11 | SKM1 | Yeast | 16 | 3.9–6.4 | PLI: PMID:15023338. Affinity, measured: same ref. |
| 12 | BEM1 | Yeast | 1037 | >100 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 13 | BOI1 | Yeast | 399 | 20 | PLI: PMID:15023338. Affinity, measured: same ref. |
| 14 | VAM7 | Yeast | 210 | 2–3 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 15 | SNX3 | Yeast | 5092 | 2–3 | PLI: PMID:11557775. Affinity, measured: same ref. |
| 16 | SLA2 | Yeast | 3904 | 0.27–3.4 | PLI: PMID:15574875. Affinity, homology (AP180): PMID: 12740367. |
| 17 | SYP1 | Yeast | 2467 | Used 0.1, 10, 100 | PLI: PMID:19713939,1321812. Affinity, not known, estimated. |
| 18 | ENT1 | Yeast | 1750 | 0.08 | PLI: PMID:22193158,10449404. Affinity, homology (EPN1): PMID:17825837. |
| 19 | ENT2 | Yeast | 1325 | 0.08 | PLI: PMID:22193158,10449404. Affinity, homology (EPN1): PMID:17825837. |
| 20 | YAP1802 | Yeast | 264 | 0.27–3.4 | PLI: PMID:22193158,21119626. Affinity, homology (AP180): PMID:12740367. |
| CHC1 (Not Studied) | Yeast | 19278 | No binding | - | |
| 21 | SLA1 | Yeast | 2964 | No binding | - |
| 22 | EDE1 | Yeast | 5964 | No binding | - |
| 23 | FCHO1 | Human | 3706 | Used 0.1, 10, 100 | PLI: PMID:22484487. Affinity, not known, estimated. |
| 24 | AP-2 | Human | 244537 | 2.86 (0.072) | PLI: PMID:15916959. Affinity, measured: same ref. |
| 25 | EPN1 | Human | 570949 | 0.08 | PLI: PMID:17825837. Affinity, measured: same ref. |
| 26 | PICALM | Human | 358673 | 2.7–3.4 | PLI: PMID:25090048. Affinity, homology (AP180): PMID:12740367. |
| 27 | DAB2 | Human | 1078162 | 0.08 | PLI: PMID:12234931. Affinity, homology (EPN1): PMID:17825837. |
| 28 | FCHO2 | Human | 36302 | Used 0.1, 10, 100 | PLI: PMID:20448150. Affinity, not known, estimated. |
| 29 | SNAP91/AP180 | Human | 21716 | 0.27–3.4 | PLI: PMID:12740367. Affinity, measured: same ref. |
| 30 | LDLRAP1/ARH | Human | 1048 | 0.08 | PLI: PMID:12234931. Affinity, homology (EPN1): PMID:17825837. |
| 31 | HIP1 | Human | 13771 | 0.27–3.4 | PLI: PMID:14732715. Affinity, homology (AP180): PMID:12740367. |
| 32 | HIP1R | Human | 24161 | 0.27–3.4 | PLI: PMID:14732715. Affinity, homology (AP180): PMID:12740367. |
| 33 | AMPH | Human | 89536 | 0.1 | PLI: PMID:22888025. Affinity, measured: same ref. |
| 34 | SH3GL2/Endophilin | Human | 55621 | 0.03 | PLI: PMID:22888025. Affinity, measured: same ref. |
| 35 | EPS15 | Human | 91354 | No binding | - |
| 36 | ITSN1 | Human | 20184 | No binding | - |
| 37 | CLTC | Human | 1495814 | No binding | - |
a) To simulate clathrin trimers, the heavy chain copy numbers reported here are divided by 3.
b) Considering AP2A1 gene.
c) Based on ppm value from PMID: 24920484. We scaled this value by the number of AP-2s from PMID: 26496610 to obtain the predicted number of AP180s in the cell.
d) Copy number for yeast from Ref. [49] and humans Ref: [50]
Fig 2The equilibrium theory developed here accurately predicts how and when membrane localization will enhance protein interaction strength.
(a) Our theory (Eq 3) shown in solid black lines in all panels, is compared with ODE simulation results shown in red circles. For reference, the blue line shows the trend for pure solution binding, i.e. Kaeff = KaPP. The green line shows the maximum achievable enhancement, occurring if all proteins were on the membrane, Kaeff = γKaPP. The gray dashed lines are included to contrast the Kaeff calculated using a simple approximation that lacks cooperativity (S1 Text section 2D). From a1 to a2, the KaPM is decreased, producing lower but still constant enhancements, as the lipids are in excess relative to the proteins. (b) The number of unbound lipids is plotted as a function of KaPP with all other parameters fixed (S1 Text section 3A), showing how lipid binding is a function of the protein interaction strength due to the cooperative effect (Fig 1D and 1E). The theoretical prediction for [M]eq is shown in solid black. (c) With fewer lipid recruiters relative to total cytosolic proteins ([P]tot/[M]tot >1), the enhancement is less pronounced, although for weak binders (low KaPP) even limited membrane localization causes significant increases in complex formation. From c1 to c2 the protein concentrations are increased. All results use σ = 1nm, see S1 Text section 3A for all other parameters. (d) If only one partner binds the membrane, the protein interaction remains fully 3D and no enhancement occurs.
Fig 3Protein interactions aided by strong protein-lipid interactions, abundant lipid recruiters, and low protein concentrations benefit most widely from membrane localization.
a,b) Enhancement ratios from ODE simulation (colored lines) and theory (black solid lines in all panels). The dashed black line is the upper limit for the enhancement ratio given by Kaeff/KaPP = γ. σ = 1nm. Between the limiting cases where the membrane surface area is either too large to enhance binding (V/A⟶0) or is too small to effect binding (V/A⟶∞), a broad region of enhanced binding occurs. The vertical gray line is the V/A ratio for the yeast plasma membrane (0.5μm), for reference, and most physiologic V/A values fall in the range ~0.05–20μm (S3 Table). Within this physiologic range of V/A values is where we generally observe the largest enhancements. The cell geometry pictures provide examples of how one can produce different V/A ratios along the x-axis relative to the central sphere. A maximum enhancement for each parameter set is reached at a value of V/A where lipids still outnumber proteins (shown on upper x axis). Increasing (a) protein-lipid affinities and (b) lipid concentrations produces greater possibilities for enhancement. (c) Increases in the membrane stickiness (KaPM[M]eq) produces monotonic increases in enhancement for all values of γ>1. (d) For lower expression levels relative to binding strength (KaPP = 106M-1), membrane localization can act as a switch to turn on assembly from <50% to >50% (shaded areas). (e) Timescales to equilibrate were calculated from simulations of both ODEs (solid lines) and reaction-diffusion (RD) (green points) (Methods). Weak lipid binding can reduce speeds (blue) relative to pure solution binding (dashed). The approximate theoretical bounds shown here for time-scales of binding either purely in solution (dashed) or on the membrane (gray) derive from the kinetics of irreversible association (S1 Text section 4C).
Fig 4Membrane localization triggers strong complex formation for pairs of protein binding partners involved in clathrin-mediated endocytosis.
(a) Interactions between lipid binding human (green) and yeast (blue) CME proteins are shown along with KdPP values (μM) measured (red text), inferred through structural and functional homology (green), or estimated (blue) (Table 1, S1 Table, S3 Dataset). Sizes indicate concentrations (Table 1). (b) Enhancements for each of these CME binding pairs, following the model of Fig 1, were calculated using Eq 3 and verified through numerical simulation of ODEs. Pairs involving human AP-2 are in dark green, light green points involve AP-2 with cargo binding-adjusted KaPM, with red and blue points showing other human and yeast proteins, respectively. The x-axis is the average membrane stickiness for each pair, and here we assume σ = 1nm (see S5 Fig for σ = 10nm). For poorly characterized lipid binding affinities, we considered ranges of values (error bars in x), producing ranges of enhancements (error bars in y). Gray lines are guides for fixed V/A ratios. Protein names in parentheses are homo-dimers. (c) The percent of proteins in complexes increases from solution binding levels (gray bars) as a result of membrane localization (colored bars). All results and parameters used for all data points in S3 Dataset.
Fig 5Scaffold-mediated interactions can also exploit membrane localization to drive complex formation in clathrin-mediated endocytosis.
a) When sets of three proteins can form a complex and two of them also bind to lipids, localization is again capable of driving stronger complex formation. Yeast proteins in blue and human proteins in green, where the uppermost four (SLA1, EDE1, EPS15, ITSN1) are scaffold proteins that do not bind lipids. Affinities follow the same color scheme as Fig 4, and we have included only binding interactions between these proteins that are shown in parts b-c. (b) Because our primary model (Fig 1) no longer applies, we cannot use Eq 3 to predict enhancements, and instead use simulations of ODEs. The scaffold model is defined in S1 Text section 1C and S7 Fig, along with the definitions of Kaeff,SP and Kasol,SP, where neither is a true equilibrium constant and the equilibrium results of the simulations are used to calculate their defined values. Without membrane localization, Kaeff,SP→Kasol,SP. Scaffold proteins (s in the labels) are eps15/ede1 (orange), or itsn1/sla1 (pink). (c) Complexation involves all three proteins (see S1 Text section 1D) and here again, the percent of proteins in complexes increases from solution binding levels (gray bars) as a result of membrane localization (colored bars). All results and parameters in S4 Dataset.